# OnCo record nct03539822 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct03539822/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct03539822", "NCT03539822" ;
  schema:name "Cabozantinib Plus Durvalumab With or Without Tremelimumab in Patients With Gastroesophageal Cancer and Other Gastrointestinal Malignancies"@en ;
  schema:alternateName "CAMILLA"@en ;
  schema:description "A phase 1/2 trial of cabozantinib, durvalumab and tremelimumab in colorectal cancer, run by Anwaar Saeed, now recruiting."@en ;
  schema:url <https://onco.cc/trials/nct03539822/> ;
  schema:dateModified "2026-09-24"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT03539822> ;
  onco:status "recruiting" ;
  onco:tag "ctgov-ingest", "colorectal-deep-dive" ;
  onco:phase "1/2" ;
  onco:cancers <https://onco.cc/cancers/rectal-cancer/>, <https://onco.cc/cancers/colon-cancer/> ;
  onco:technologies <https://onco.cc/technologies/checkpoint-inhibitor/> ;
  onco:drugs <https://onco.cc/drugs/cabozantinib/>, <https://onco.cc/drugs/durvalumab/>, <https://onco.cc/drugs/tremelimumab/> ;
  onco:companies <https://onco.cc/companies/astrazeneca/>, <https://onco.cc/companies/exelixis/> .